Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Here we share a short video introducing Metrion’s extensive suite of cardiac safety screening services. To learn more, or to request a quote, please email info@metrionbiosciences.com
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.